Candriam SCA
TRVI icon

Candriam SCA’s Trevi Therapeutics TRVI Stock Holding History

Candriam SCA’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.8M Buy
1,308,104
+341,885
+35% +$5.88M 0.08% 205
2026
Q2 		$18M Buy
966,219
+192,599
+25% +$2.8M 0.08% 216
2026
Q1 		$9.23M Buy
+773,620
New +$8.66M 0.05% 291

Other funds holding TRVI

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.25B AUM 28.18% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
PFS Partners
PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Harbour Capital Advisors
Harbour Capital Advisors Tysons Corner, Virginia $548M AUM 37.76% 1-Year Est. Return

Candriam SCA's TRVI Position: Q3 2026 in Review

Candriam SCA increased its Trevi Therapeutics (TRVI) stake by 35% in Q3 2026, buying an estimated $5.88M and bringing the position to 1,308,104 shares worth $18.8M. The position accounts for 0.08% of the portfolio, ranked #205.

Candriam SCA first reported a position in TRVI in Q1 2026 and has held it in 3 quarters since. 49 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Candriam SCA held 1,308,104 shares of Trevi Therapeutics worth $18.8M as of Q3 2026.
  • Candriam SCA bought 341,885 Trevi Therapeutics shares in Q3 2026, an estimated $5.88M.
  • Trevi Therapeutics made up 0.08% of Candriam SCA's portfolio in Q3 2026, its #205 holding.
  • Candriam SCA first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 49 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.